3 March 2021 - Eli Lilly’s Olumiant has received a UK NICE recommendation for the treatment of moderate-to-severe atopic dermatitis (atopic eczema) in adults.

NICE has backed use of Olumiant (baricitinib) for patients whose disease has not responded to at least one systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil or where these are not suitable.

Read Pharma Times article